

# The Clinical and Economic Impact of ROTEM-Guided PBM in Cardiac Surgery

## Management of bleeding complications related to cardiac surgery

Nearly 1 million coronary artery bypass graft (CABG) surgeries are performed annually worldwide. These surgeries:<sup>1</sup>

- Consume approximately 20% of all blood products transfused
- Include acquisition costs of >\$700 for all blood components transfused per patient\*

Though cardiac surgeries are frequent and bleeding incidence is high, treatment and transfusion vary significantly.

At hospitals performing  $\geq 100$  on-pump CABG surgeries, there is a high variation in rates of blood transfusion:<sup>3</sup>

- 7.8–92.8% for red blood cells
- 0–97.5% for fresh frozen plasma
- 0.4–90.4% for platelets

### High incidence of bleeding complications

The rate of bleeding complications in cardiac surgery is **47.4%**, the **highest among all surgical subgroups.**<sup>2</sup>



### Bleeding complications and resultant transfusions negatively impact clinical outcomes, leading to increased:<sup>4-7</sup>


- Morbidity and mortality
- Hospital length of stay (LOS)
- Avoidable complications

\*Corresponds roughly to USD \$3,500 in activity-based costs.<sup>8</sup>

## Viscoelastic testing for cardiac surgery patients

Early diagnosis and goal-directed therapy to correct an underlying hemostatic abnormality is highly effective. Moreover, algorithm-based therapy has demonstrated superiority to empiric treatment.<sup>4</sup>

### Viscoelastic testing can reduce transfusions



### Potential reduction in

Total transfusions

**17%**

Red blood cells

**17%**

Fresh frozen plasma

**64%**


Platelets

**10%**


ROTEM *delta* is FDA 510(k)-cleared and Canada-licensed for laboratory use only and not at the point of care.

# ROTEM-guided management can improve clinical outcomes in cardiac surgery



Several studies in cardiac surgery have shown significant improvements in clinical outcomes by implementing ROTEM-guided, patient-centered treatment concepts.



Potential reduction in  
Acute Renal Failure (ARF)  
**70%**  
Sepsis  
**86%**  
Thromboembolic events  
**100%**  
Composite adverse events  
**79%**



Potential reduction in  
Chest wound infection  
**57%**  
Leg wound infection  
**57%**  
Re-exploration  
**39%**



**ROTEM-guided bleeding management reduces:**  
Mortality<sup>7</sup>  
**56%**  
compared to controls<sup>8</sup>

Implementing ROTEM-guided management in cardiac surgery addresses the high incidence of bleeding complications by providing **early diagnosis for goal-directed treatment decisions**. This results in **improved patient care and experience**.

#### References

- Snyder-Ramos SA, Möhnle P, Weng Y, Böttiger BW, Kulier A, Levin J, et al. The ongoing variability in blood transfusion practices in cardiac surgery. *Trans*. 2008;48(7):1284–1299.
- Stokes ME, Ye X, Shah M, Mercaldi K, Reynolds MW, Rupnow MFT, Hammond J, et al. Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. *BMC Health Serv Res*. 2011;11:135.
- Bennett-Guerrero E, Zhao Y, O'Brien SM, Ferguson TB Jr, Peterson ED, Gammie JS, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. *JAMA*. 2010;304(14):1568–1575.
- Weber CF, Görlinger K, Meiningner D, Herrmann E, Bingold T, Moritz A, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. *Anesthesiol*. 2012;117(3):531–547.
- Pearse BL, Smith I, Faulke D, Wall D, Fraser JF, Ryan EG, et al. Protocol guided bleeding management improves cardiac surgery patient outcomes. *Vox Sang*. 2015;109(3):267–279.
- Nakayama Y, Nakajima Y, Tanaka KA, Sessler DI, Maeda S, Iida J, et al. Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and red cell transfusion after paediatric cardiac surgery. *Br J Anaesth*. 2015;114(1):91–102.
- Wikkelse A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. *Cochrane Database Syst Rev*. 2016;(8):CD007871.
- Deppe AC, Weber C, Zimmermann J, Kuhn EW, Stottosch I, Liakopoulos OJ, et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. *J Surg Res*. 2016;203(2):424–433.

[werfen.com](http://werfen.com)

**For more information, contact your local Werfen sales representative or distributor.**

GEM, Premier, GEM Premier ChemSTAT, ChemSTAT, GEMweb, iQM, Hemochron, VerifyNow, Avoximeter and ROTEM are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies and may be registered in the United States Patent and Trademark Office and in other jurisdictions. The Werfen logo is a trademark of Werfen and may be registered in the Patent and Trademark Offices of jurisdictions throughout the world. All other product names, company names, marks, logos and symbols are trademarks of their respective owners.

©2022 Instrumentation Laboratory. All rights reserved.

**werfen**